Evidence map›Paper›PMID 41909678›Full record

ArticleFrontiers in immunology2026

Ruxolitinib reverses systemic vasculitis driven by JAK2 V617F-mutated essential thrombocythemia: a case report.

Yutaro Ashida, Shinji Ota, Nao Ishidoya, Yasuhisa Murai, Kyoko Amenomori, Keisuke Hasui, Shogo Kawaguchi, Satoko Yamaguchi, Hiroto Hiraga, Kosuke Kamata and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yutaro Ashida *Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Shinji Ota *Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Nao IshidoyaDepartment of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Yasuhisa MuraiDepartment of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Kyoko AmenomoriDepartment of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Keisuke HasuiDepartment of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Shogo KawaguchiDepartment of Vascular and Inflammatory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Satoko YamaguchiDepartment of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hiroto HiragaDepartment of Bioscience and Laboratory Medicine, Hirosaki University Graduate School of Health Sciences, Hirosaki, Japan.
Kosuke KamataDepartment of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hiroaki IchikawaDepartment of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hirofumi TomitaDepartment of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Zaiqiang YuDepartment of Thoracic and Cardiovascular Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Masahito MinakawaDepartment of Thoracic and Cardiovascular Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hirotake SakurabaDepartment of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Vasculitis associated with myeloproliferative neoplasms is rare, and reports on its treatment are limited. Herein, we report a case of Case presentation: A 60-year-old man with Conclusion: This rare case shows that ruxolitinib can be effective in treating vasculitis complications in patients with

Indexed as

Janus Kinase 2MutationPyrazolesThrombocythemia, EssentialVasculitisHumansMaleMiddle AgedNitrilesPyrimidinesTreatment OutcomeJAK2 protein, humanJanus Kinase 2NitrilesPyrazolesPyrimidinesruxolitinibJAK2 V617F mutationmyeloproliferative neoplasmsruxolitinibthrombocythemiavasculitis

Identifiers

PMID41909678
PMCPMC13021485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.